PDCD1 and autoimmune disease: Blocking the PD1 checkpoint inhibitor by anti‐PD1 Abs has been an effective strategy to treat various malignancies, although there are still concerns about the off‐target effects of using high‐affinity Abs and the development of autoimmune diseases.